Table 2 Clinical and pathological data of patients included in miR-375 validation
From: MicroRNA-375 plays a dual role in prostate carcinogenesis
Clinicopathological data | Tumors ( n = 114) | MNPT ( n = 15) |
|---|---|---|
Age (years), median (range) | 65 (49 to 74) | 64 (45 to 80) |
PSA (ng/mL), median (range) | 8.00 (2.66 to 20.00) | n.a. |
Pathological stage, n (%) | ||
pT2 | 58 (38.7%) | n.a. |
pT3a | 24 (16.0%) | n.a. |
pT3b | 33 (21.3%) | n.a. |
Gleason score, n (%) | ||
<7 | 28 (18.7%) | n.a. |
=7 | 73 (48.7%) | n.a. |
>7 | 13 (8.7%) | n.a. |